Traditionally, protein expression in E. coli is achieved either through cytoplasmic production as inclusion bodies or through secretion into the periplasmic space.  SoluPro™ expresses soluble, disulfide linked proteins through production in a semi-oxidized cytoplasm.

SoluPro’s™ precisely tunable dual inducer system achieves peak production using straightforward induction titrations. Below is an example of Fab expression.

SoluPro™ speeds the time it takes to get new medicines to market by accelerating, or in some cases, cutting out steps entirely from the drug discovery and clinical development process. During development, SoluPro™ can produce gram quantities of material for preliminary screenings in a matter of days instead of weeks. In addition, because SoluPro™ has a demonstrated track record expressing difficult proteins and achieves higher protein production levels than mammalian systems, scientists can now access previously elusive and untestable therapeutic proteins. Once therapeutic candidates have been identified, the platform scales seamlessly for commercial production, therefore eliminating the 6-12 month cell-line development process.

At scale, SoluPro™ creates breakthrough efficiencies in biomanufacturing, eliminating the need for large plant build-outs and reducing drug substance costs by 50-80% for high-volume medicines such as insulin. By returning biomanufacturing to its E. coli roots, AbSci aims to replace CHO and other mammalian expression platforms as the expression host of choice.